Q-omics provides the consensus-scored CSNK1E profile across patient tissues and cancer cell-line models. CSNK1E expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CSNK1E is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CSNK1E RNA expression shows 20,574 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where CSNK1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSNK1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSNK1E survival associations across molecular data types. CSNK1E RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSNK1E RNA expression–survival associations across cancer types. High CSNK1E expression shows unfavorable associations in ACC, LIHC, LUAD, SKCM, LUSC and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CSNK1E RNA expression.
This table summarizes CSNK1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CSNK1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSNK1E shows higher tumor expression in HNSC, KIRC, COAD, LIHC, READ and LUSC. The HNSC box plot shows higher CSNK1E RNA expression in tumor versus normal tissue (log2 FC = +1.448, t-test p < 0.001).
This table shows molecular features associated with CSNK1E in patient tissues and cancer cell lines. In patient samples, CSNK1E shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CSNK1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
